Limitations Reflect Gaps in Ophthalmologic Monitoring The researchers acknowledged several study limitations, including substantial variability in assessment methods, the absence of a specific ICD-10 code for NAION, and the exclusion of participants with advanced diabetic eye disease, and stressed the need for additional research regarding the relationship between semaglutide and NAION The authors concluded, Treatment with semaglutide in adults was not associated with an increased risk of eye disorders or DR in this study, and future studies are unlikely to change these results
But using it too often or at a high strength can result in irritation
When to Consider Dose Adjustment or Medication Change In some cases, the severity of hair loss or other side effects may warrant reconsidering your GLP-1 treatment approach: Considerations for Adjustment: Extremely rapid weight loss (more than 3 pounds weekly sustained) Severe hair shedding thats psychologically distressing Inability to maintain adequate nutrition despite best efforts Multiple concerning side effects beyond hair loss Options to Discuss with Your Provider: Reducing GLP-1 dose to slow weight loss Switching to a different GLP-1 medication Taking a medication holiday to allow stabilization, then resuming Exploring alternative weight loss approaches Critical Point: Dr
As a woman ages, her ovaries start losing the ability to produce estrogen
The FDA just put BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, and DSIP on the July 23-24, 2026 PCAC agenda